Floatz logo

ATORVASTATIN

Hyperlipidemia

Poznan University of Medical SciencesSmall moleculePhase 4 / ApprovedDormant
BBB
79/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Hyperlipidemia cohort.

Asset / SponsorPhaseRating
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
PRAVASTATIN
University of North Carolina, Chapel Hill
Phase 4BBB
Ezetimibe
NewAmsterdam Pharma
Phase 4BBB
Fenofibrate
Ospedale di Circolo - Fondazione Macchi
Phase 4BB
Darunavir
University of Colorado, Denver
Phase 4BB

View all 35 →

Same molecule, other indications

ATORVASTATIN is also rated in:

inherited lipid metabolism disorderActive
A
Indicative · Phase 4
83 / 100
View asset →
cardiovascular disorderActive
BBB
Indicative · Phase 4
76 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →